PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a gl ...

Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth quarter and fiscal year Adjusted non-GAAP net income of $34.2 million, or $0.73 per share and $156.6 million, or $3.25 per share, respectively, for the fourth quarter and fiscal year Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA ...

Shares of Novo Nordisk (NYSE: NVO) sank 20% this week, according to data from S&P Global Market Intelligence. The drugmaker behind the weight-loss drug craze is in the midst of a terrible drawdown -- 75% as of this writing -- due to a bad trial for its new weight-loss drug in a head-to-head battle with Eli Lilly. Plus, the company announced additional price cuts for its weight-loss drug Wegovy in 2027, due to pressure from the U.S. government. Here's why Novo Nordisk stock fell again this week, and wheth ...

A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel on Sept. 9, 2025.Novartis, one of the world's largest pharmaceutical companies, and Genentech, a major biotech firm, say they've uncovered a "dangerous scheme" to import their allergy medication from Canada into the U.S. in violation of U.S. Food and Drug Administration regulations.Both are suing SHARx — a so-called alternative funding program — and a Canadian pharmacy over the importation of Xolair, a ...

historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward- looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential", "continue", "budget", "scheduled", ...

Core Insights - The article discusses preliminary results from a Phase 1b study of pasritamig (JNJ-78278343), a bispecific T-cell engaging antibody, in combination with docetaxel for treating metastatic castration-resistant prostate cancer [1] Group 1: Study Results - The combination therapy demonstrated deep prostate-specific antigen (PSA) responses, indicating its potential effectiveness in treating the disease [1] - The safety profile of the treatment was reported as favorable, suggesting a manageable side effect profile for patients [1] Group 2: Future Plans - Johnson & Johnson plans to advance the therapy into Phase 3 clinical trials, indicating confidence in the drug's potential [1] - The study highlights the potential of this first-in-class therapy to expand the role of immunotherapy in prostate cancer treatment [1]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not beDallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron.” As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remai ...

For the quarter ended December 2025, Collegium Pharmaceutical (COLL) reported revenue of $205.45 million, up 12.9% over the same period last year. EPS came in at $2.04, compared to $1.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $208.65 million, representing a surprise of -1.53%. The company delivered an EPS surprise of -6.99%, with the consensus EPS estimate being $2.19.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

A giant in the healthcare space, Merck ( NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week. ...